Aprea Therapeutics, Inc.
APRE
NASDAQ·Healthcare·Biotechnology·Mkt cap $9.8M
$0.71
▼ -5.36%
P/E
—
Mkt Cap
$9.8M
52-Wk Range
$0.55–$1.69
52-Week Range
$0.55 - $1.69
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 51.1% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
4 reasons
- Proprietary DNA damage response pathway targeting technology
- Oral formulation of ATR inhibitor improving patient accessibility
- Experienced clinical development team in oncology therapeutics
- Diversified pipeline with multiple DDR-targeting candidates
Bear Case
1 risk
- Above-average volatility (beta 1.6).
Growth
Stable outlook
Phase 1/2a clinical trial progression of ATRN-119
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Stable
-2.4% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying APRE right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 5, 2026
AUG 12, 2026
Reported EPS of -$0.07 vs -$0.18 consensus (+60.6% surprise).
EPS surprise · last 4Q
1 of 1 beats
Estimate
Actual
Q3 26
+60.6%
Revenue trend · last 8Q
—
—
-57%
-79%
-99%
-98%
-100%
-100%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$354.6K
$205.8K
$162.5K
$118.1K
$1.8K
$3.3K
$0
$0
Margins · last 8Q
Profit
—
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Wedbush · May 14, 2026
vs Industry
How APRE stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related